<DOC>
	<DOCNO>NCT02959905</DOCNO>
	<brief_summary>The primary purpose study evaluate safety TSA-CTL treatment advance melanoma . The secondary purpose study evaluate preliminarily effect TSA-CTL treatment advance melanoma .</brief_summary>
	<brief_title>Treatment Metastatic Melanoma With TSA-CTL ( Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Greater equal 18 year age less equal 70 year age；all gender . 2 . Confirmation diagnosis metastatic melanoma Laboratory Pathology . 3 . Measurable metastatic melanoma least one lesion resectable tumor biopsy DNA extraction . 4 . The Malignant skin mucosal melanoma patient HLA A0201 subtypes . 5 . The advanced melanoma patient fail conventional treatment receive least routine treatment metastatic melanoma ( chemotherapy、PD1antibody、CTLA4 antibody target therapeutic ) . 6 . Able understand sign Informed Consent Document.Willing sign durable power attorney . 7 . Clinical performance status ECOG 0 1 Life expectancy great six months；able cooperate observe adverse reaction effect treatment . 8 . Patients gender must willing practice birth control time enrollment study twelve month treatment . 9 . Women childbearing potential must negative pregnancy test potentially dangerous effect treatment fetus . 10 . Serology：Seronegative HIV antibody，Seronegative hepatitis B antigen , seronegative hepatitis C antibody . Hematology：Absolute neutrophil count great 1000/mm ( 3 ) without support filgrastim，WBC great equal 3000/mm ( 3 ) ，lymphocyte count great equal 800/mm ( 3 ) ，Platelet count great equal 100,000/mm ( 3 ) ，Hemoglobin &gt; 9.0 g/dl Chemistry：Serum ALT/AST less equal 2.5 time upper limit normal，Serum Creatinine le equal 1.6 mg/dl，Total bilirubin less equal 1.5 mg/dl , except patient Gilbert Syndrome must total bilirubin less 3.0 mg/dl . 11 . More four week must elapse since prior systemic therapy time patient receives preparative regimen , patient toxicity must recover grade 1 less ( except toxicity alopecia vitiligo ) .Note : Patients may undergo minor surgical procedure within past 3 week , long toxicity recover grade 1 less . 12 . Eight week must elapse time antibody therapy could affect anti cancer immune response , include antiPD1 antibody antiCTLA4 antibody therapy , time patient receives preparative regimen allow antibody level decline . 1 . Women childbearing potential pregnant breastfeed potentially dangerous effect treatment fetus infant . 2 . Any form primary immunodeficiency ( Severe Combined Immunodeficiency Disease ) . 3 . Concurrent opportunistic infection ( The experimental treatment evaluate protocol depends intact immune system . Patients decrease immune competence may less responsive experimental treatment susceptible toxicity ) . 4 . The medical history autoimmune disease . 5 . Active systemic infection , coagulation disorder active major medical illness cardiovascular , respiratory immune system . 6 . Concurrent systemic steroid therapy . 7 . History severe immediate hypersensitivity reaction agent use study . 8 . Patients generate level 34 correlation adverse reaction antiPD1/PDL1 antibody treatment . 9 . Patients brain metastasis . 10 . The choroid melanoma clear cell sarcoma patient . 11 . Negative expression MHC molecule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>